AbstractWe have presented pharmacokinetic parameters of bromperidol (BP) in 14 healthy Korean subjects. Additionally, we have investigated the effects of dose and genetic polymorphisms on BP metabolism and on extrapyramidal symptoms (EPS). The Tmax (3.9 ± 0.9 h), clearance (1.37 ± 0.52 ml/h/kg), and t1/2 (20.4 ± 3.7 h) obtained in our study are comparable to those in previous Caucasian studies, although pharmacokinetic profiles were affected by the BP dose. We could not prove any significant correlations between BP metabolism or adverse effects and genetic factors because the number of subjects was small. Further studies with a larger population are needed to determine the influence of genetic factors on BP therapy. Copyright © 2006 John Wiley & Sons, Ltd.